Search results for: Multi-Indication Medicines
Filter search results
What the first EU JCA reveals about assessing precision oncology
28 July 2026
…population, it also means that a single JCA may need to evaluate evidence generated across multiple tumour types, each with different comparators, treatment pathways, and standards of care, but often with a small or immature evidence base. Meeting the evidence requirements for multiple…
Assessing the Life-cycle Value of Second-generation Antipsychotics in Sweden and the UK
17 July 2019
…A. & Zamora, B., 2019. Indication-Based Pricing (IBP) Discussion Paper. OHE Briefing, London: Office of Health Economics. Available at: https://www.ohe.org/publications/indication-based-pricing-ibp-discussion-paper-should-drug-prices-differ-indication Lakdawalla, D., MacEwan, J.P., Dubois, R., Westrich, K., Berdud,…
Reasons for Discontinuation of R&D Projects: Lead and Follow-on Indications
12 March 2013
…lead indications were consistent with previous findings; to our knowledge, this is the first analysis of discontinuations of follow-on indications. Companies also were asked their opinions on what factors may…
The value of cell and gene therapies to the UK economy
20 October 2025
…projected to create value between £20-40 billion across the four case study indications, depending on the category of value considered. AD dominates the aggregate because of its prevalence, but every indication is…
The US Inflation Reduction Act: What Do the Experts Think?
25 May 2023
…15 years to around 10. Companies may need to think more strategically about launch indications. Importantly, incentives for manufacturers to research and invest in new indication launches for existing therapies…
Is the revised Congressional Budget Office model of new drug development fit for purpose?
6 May 2026
…of existing drugs, which represents a critical source of treatment advances for patients, particularly in areas such as oncology and rare disease. Considering the dominance of multi-indication drugs in some…
NICE at 25: Technology Appraisals – Faster Access to Modern Treatment?
1 May 2024
…and prices for medicines. Beta-Interferon, a new treatment for Multiple Sclerosis (a disease that was poorly served by existing treatments), was the driver for taking the step. The evidence for…
OHE Presentations at HTAi: Tokyo 2016
24 May 2016
…can HTA’s in Asia respond to Increased Clinical Uncertainty: the potential for PBRSAs from Office of Health Economics Making Value-Based Pricing a Reality – the Case for Multi-Indication Pricing by…
Advancing Rare Disease Care: Challenges and Key Issues
28 February 2025
…(approved through the Innovative Medicines Fund). Of relevance to ultra-rare diseases in the UK, Highly Specialised Technologies (HST) guidance provides a route to appraisal and access for some orphan medicines,…